NLRP3 and prostate carcinoma: In support of this, the molecular mechanism by which the overactivation of the NLRP3 inflammasome promotes the malignant progression of prostate cancer has been defined, proposing this inflammasome as a new prognostic biomarker and potential therapeutic target for this cancer [22].